Genetic Technologies Profit Margin

The latest profit margin for GENE is -147.04% as of June 2024. That compares with -103.65% in the prior-year period — down 41.9% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Genetic Technologies's historical trend and sector peers before judging valuation or financial health.

Over the past year, GENE's profit margin moved from -103.65% to -147.04% — a 41.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Genetic Technologies's valuation or profitability profile.

Against Healthcare companies, GENE currently prints -147.04% for profit margin, while the sector average sits near 15.29%. That is roughly 1061.5% below the sector mean. Large gaps often invite a closer look at Genetic Technologies's growth, margins, and balance sheet.

Profit Margin shows how effectively Genetic Technologies converts resources into returns. At -147.04%, GENE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -103.65% in the prior-year period — down 41.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting GENE's profit margin (-147.04%), review year-over-year change from -103.65%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.